Somatic TET2 deficiency contributes to immune dysregulation with advanced age 12 and is reported to occur in approximately 50% of angioimmunoblastic T-cell lymphomas and 20 to 40% of PTCL-NOS ...

Kennedy researchers have uncovered key design parameters for bispecific T-cell engagers (TcEs)—a class of cancer immunotherapy drugs. The findings may help unlock the full potential of TcEs and ...

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...

Most patients who have a relapse after anti-CD19 CAR T-cell therapy or have resistance to such therapy continue to have CD19 expression on malignant B cells. 11 Although CD19 antigen loss can ...

CAR T cell therapy is an approach in which scientists genetically engineer a patient’s own immune cells to make a new protein, turning them into supercharged cancer fighters. The treatment appears to ...